Engineers Gate Manager’s AIM ImmunoTech AIM Stock Holding History

Engineers Gate Manager’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-179	Closed	-$41K	–	2242
2021 Q1	$41K	Buy	+179	New	+$40.4K	﹤0.01%	1758

Other funds holding AIM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Engineers Gate Manager's AIM Position: Q2 2021 in Review

Engineers Gate Manager sold out of AIM ImmunoTech (AIM) in Q2 2021, closing a stake of 179 shares — an estimated $41K sold.

Engineers Gate Manager first reported a position in AIM in Q1 2021 and held it in 1 quarter. The position peaked at $41K in Q1 2021. 35 funds tracked by Wall St. Rank hold AIM as of Q2 2021.

Engineers Gate Manager reported no remaining AIM ImmunoTech position as of Q2 2021 after selling out during the quarter.
Engineers Gate Manager sold 179 AIM ImmunoTech shares in Q2 2021, an estimated $41K.
Engineers Gate Manager first reported a position in AIM ImmunoTech in Q1 2021 and held it in 1 quarter.
Engineers Gate Manager's AIM ImmunoTech position peaked at $41K in Q1 2021.
35 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2021.

Based on Engineers Gate Manager's 13F filing for Q2 2021, filed 16 Aug 2021.